| Species |
Human |
| Protein Construction |
| His |
Fas Ligand/TNFSF6 (Pro134-Leu281)
Accession # AAH17502.1 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Fas Ligand/TNFSF6, His, Human at 2μg/ml (100μl/Well) on the plate can bind Human Fas, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
18 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 20-35 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Fas ligand (FasL, CD95L) is a 40-kDa type II transmembrane protein that binds to Fas (CD95) receptors and promotes programmed cell death. Fas receptors are expressed at higher levels in many tumors than in normal cells.Somewhat paradoxically, elimination of Fas or FasL from tumors also leads to death induced by CD95 receptor/ligand elimination (DICE). |
| Synonyms |
APTL; CD95-L; Fas ligand; APT1LG1; TNFSF6; FASLG; ALPS1B; CD178; FASL; TNLG1A |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
